Location Directory

Clinical trials in Ann Arbor, Michigan

This page shows live ClinicalTrials.gov search results for Ann Arbor, Michigan, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1806

Shown on this page

Local exact-city summaries

1806

Based on exact city/state matches in the local index.

Local exact-city recruiting

969

Live official results below use the broader ClinicalTrials.gov location search.

The trial list below is retrieved from the live ClinicalTrials.gov search API for Ann Arbor, Michigan. Results on this page are currently sorted by Recently updated. Use the filter controls below to narrow by condition, treatment, sponsor, recruitment status, phase, study type, sex, or age.

Showing 1–12 of 1,806 matching trials in Ann Arbor, MI.

Indexed local directory records.

The summary panels and records below use exact city/state matches from the local directory for Ann Arbor, MI. Use the filters or full search link when you want broader live ClinicalTrials.gov location matching.

Top conditions in local exact-city summaries

Malignant Solid Neoplasm 25 Breast Cancer 23 Multiple Myeloma 22 Prostate Cancer 19 Recurrent Malignant Solid Neoplasm 19 Acute Myeloid Leukemia 18

Top sponsors in local exact-city summaries

University of Michigan 211 National Cancer Institute (NCI) 192 University of Michigan Rogel Cancer Center 63 Children's Oncology Group 56 Alliance for Clinical Trials in Oncology 43 AstraZeneca 40

Top therapies in local exact-city summaries

Cyclophosphamide 60 Carboplatin 56 Pembrolizumab 56 Cisplatin 53 Paclitaxel 43 Dexamethasone 40

Indexed official records

Open in full search

Conditions: HCC
Interventions: Electroporation Device, GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, INO-9012; Device · Biological
Lead sponsor: Geneos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 7
States / cities: Atlanta, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more

Conditions: Episodic Migraine
Interventions: Atogepant, Placebo-Matching Atogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 42
States / cities: Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 36 more

Conditions: Metastatic Colorectal Cancer
Interventions: Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin, Panitumumab, Telisotuzumab Adizutecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 17
States / cities: Duarte, California • Santa Monica, California • New Haven, Connecticut + 14 more

Conditions: Essential Thrombocythemia
Interventions: Best Available Treatment, INCA033989; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 41
States / cities: Gilbert, Arizona • Tucson, Arizona • Duarte, California + 33 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions: Biospecimen Collection, Cyclophosphamide, Doxorubicin, Durvalumab, Genetic Testing, Mammography, Paclitaxel, Quality-of-Life Assessment; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3,680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 553
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 425 more

Conditions: Stroke
Interventions: Pamphlet-Supported Hand Activity, Technology-Supported Hand Training; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: Amivantamab, Carboplatin, Paclitaxel, Pembrolizumab; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 15
States / cities: La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 12 more

Conditions: Malignant Glioma
Interventions: Biopsy Procedure, Magnetic Resonance Imaging, Radiation Therapy, Selinexor; Procedure · Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 109
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 91 more

Conditions: Hematological Malignancies
Interventions: Talquetamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 14
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 10 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Obinutuzumab, Questionnaire Administration, Venetoclax; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 623
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 443 more

Conditions: Pancreatic Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Endoscopic Ultrasound-Guided Fine-Needle Aspiration, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure; Procedure · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 50 Years to 75 Years
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 413
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 294 more

Conditions: Solid Tumors
Interventions: BMS-986504, Carboplatin, Daraxonrasib, Gemcitabine, Nab-paclitaxel, Nivolumab + Relatlimab FDC, Paclitaxel, Pemetrexed, Pumitamig, Temozolomide; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 16
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more

Clinical trials in Ann Arbor, Michigan

Filter and sort this location

Top conditions in local exact-city summaries

Top sponsors in local exact-city summaries

Top therapies in local exact-city summaries

Indexed official records

Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Telerehabilitation for Post-Stroke Hand Function

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)